to improve understanding of and treatment for this disease. Conference panels included experts selected by the directors to ensure authoritative presentations on key topics and productive discussions on research directions. The question-and-answer sessions after each set of talks encouraged brainstorming between panelists and the audience of child neurologists about the best directions of future research and how clinicians can contribute.
In the conference's first session, "Clinical Neurology of SMA," we reviewed the history, clinical profiles, and current diagnostic and management strategies of this heterogeneous neuromuscular disorder. In the second session, "Molecular Mechanisms in SMA," we addressed the disorder's molecular causes, explained what is known about SMN function in the cell and its importance to neuromuscular development, and described the animal models developed for this disease. These presentations provided the audience with an understanding of phenotypegenotype correlations in SMA.
In the third session, "Translational Research," we described the search for active compounds and current animal research studies laying the groundwork for human trials. In addition, we discussed the recently formulated standards of care for patients with spinal muscular atrophy and their implications for therapy. The final session, "Future Directions," focused on approaches to therapy and current or proposed research on spinal muscular atrophy and other neuromuscular diseases as priorities of the National Institute of Neurological Disorders and Stroke (NINDS). The last session included a panel discussion moderated by Dr Jill Heemskerk (program director, NINDS), Jill Jarecki (research director, Families of SMA [FSMA]), and Cynthia Joyce (SMA Foundation), who provided insights into advances for the benefit of patients and families. FSMA, along with help from the Claire Altman Heine Foundation, organized a highly informative lunchtime program that provided attendees with a better understanding of the needs and priorities of patients and their families. Thanks to a generous grant from Fight SMA, the overall program was enhanced by the participation of 20 young investigators nominated by their mentors to attend the meeting.
I wish to express my sincere appreciation to the NINDS, the NIH Office of Rare Diseases, the Child Neurology Society, FSMA, and the Claire Altman Heine S cientific advances have improved our understanding of the pathogenesis of many disorders characterized by neurological dysfunction, and as a result, new diagnostic tools and therapies have been developed and refined. The rapid pace of discovery in basic and clinical neurosciences continues unabated. The challenge for today's practitioners? To determine which molecular diagnostic strategies, sophisticated neuroimaging tools, or innovative therapies should be adopted to manage problems ranging from common disorders to the numerous conditions that affect the developing nervous system.
Since 2001 The conference format included formal presentations, question-and-answer sessions, panel discussions, and open discussions to directly address conference objectives. The symposium directors, Drs Susan Iannaccone, Christine DiDonato, and Kathryn Swoboda, all highly respected leaders in the field of spinal muscular atrophy, had proposed the following specific objectives (in addition to the overall aims listed above): (1) to review the clinical characteristics of spinal muscular atrophy; (2) to describe what is known about the underlying neuropathology, neurobiology, and molecular biology; (3) to review translational issues in the field, such as the search for active compounds, animal models, and human trials; and (4) to discuss the standard of care for spinal muscular atrophy and identify research necessary Foundation for cosponsoring the conference, and to Fight SMA for making it possible for 20 young investigators to attend an expanded young investigator program for Neurobiology of Disease in Children. I thank symposia directors Drs Susan Iannaccone, Christine DiDonato, and Kathryn Swoboda for ensuring quality presentations and discussions and for producing a wonderful symposium. Last, I wish to express my deep gratitude to the Child Neurology Society members who attend these annual symposia and who contribute to scientific advances by sharing their observations, opinions, and questions.
A specific aim of the Neurobiology of Disease in Children conferences is to disseminate symposia proceedings to ensure that clinicians and basic scientists are well informed about scientific advances, current research initiatives, and future directions. This issue of the Journal of Child Neurology features a series of papers prepared by conference participants and edited by Melanie Fridl Ross, MSJ, ELS. 
